Short-term chlorambucil for refractory uveitis in Behcet's disease

Mudun, Abdulbaki; Ergen, Andaç; Ipcioglu, Sermin Unal; Burumcek, Engin; Durlu, Yusuf K.; Arslan, M. Okan

doi:10.1076/ocii.9.4.219.3957

Cited by 62 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A retrospective study of BD patients with refractory uveitis treated with short-term chlorambucil improved ocular involvement in 2/3 of cases and reduced the number of attacks [97].…”

Section: Alkylating Agents (Chlorambucil and Cyclophosphamide)mentioning

confidence: 99%

Behçet's disease – a contemporary review

Mendes

Correia

Barbedo

et al. 2009

Journal of Autoimmunity

271

275

View full text Add to dashboard Cite

“…A retrospective study of BD patients with refractory uveitis treated with short-term chlorambucil improved ocular involvement in 2/3 of cases and reduced the number of attacks [97].…”

Section: Alkylating Agents (Chlorambucil and Cyclophosphamide)mentioning

confidence: 99%

Behçet's disease – a contemporary review

Mendes

Correia

Barbedo

et al. 2009

Journal of Autoimmunity

271

275

View full text Add to dashboard Cite

“…Uncontrolled case series make up most of the evidence for the effectiveness of cyclophosphamide and chlorambucil in uveitis [129, 130, 131, 132]. Only one randomised controlled trial was found that compared the efficacy of prednisolone, azathioprine and cyclophosphamide for treating idiopathic uveitis in 32 patients: azathioprine was found to be more effective of the three in controlling inflammation [133].…”

Section: Treatment Optionsmentioning

confidence: 99%

Uveitis: A Potentially Blinding Disease

Durrani¹,

Meads

Murray³

2004

Ophthalmologica

262

170

View full text Add to dashboard Cite

Uveitis (intraocular inflammation) is a potentially blinding group of, probably autoimmune, conditions predominantly occurring in the working age group. Although the aetiology is unknown in most cases, many patients have an associated underlying systemic disease. Central vision loss, in the form of cystoid macular oedema, is the commonest type of visual impairment. Although historical incidence and prevalence data exists, little is known about the degree of vision loss experienced, and the social and financial consequences of having temporary or permanent visual impairment in this age group. The literature is also full of uncontrolled studies and case reports of different modalities of drug therapy for uveitis. This article attempts to raise the awareness of uveitis as an important sight-threatening group of conditions by highlighting the paucity of evidence-based data on epidemiological, quality of life, socioeconomic, and therapeutic aspects.

show abstract

“…47,58,87,92,[155][156][157][158][159][160][161][162] Remission was achieved in 70% of patients treated with chlorambucil with an average follow-up of 4 years. Forty-seven percent had at least 2 lines of improvement in Snellen visual acuity.…”

Section: Chlorambucil/leukeranmentioning

confidence: 99%